Thrb receptor agonist compound and preparation method and use thereof

ABSTRACT

The present invention discloses a compound represented by the following Formula (I) and a pharmaceutically acceptable salt thereof. The compound improves the THRα selectivity while maintaining good THRβ agonistic activity, thereby improving properties of the finished drug.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.17/951,883, filed Sep. 23, 2022, which is a continuation of U.S. patentapplication Ser. No. 17/675,690, filed Feb. 18, 2022, now abandoned,which is a continuation of U.S. patent application Ser. No. 17/305,302,filed Jul. 2, 2021, now abandoned, which is a continuation of U.S.patent application Ser. No. 16/712,301, filed Dec. 12, 2019, now U.S.Pat. No. 11,084,802, which claims priority to Chinese Patent ApplicationNo. 201811527414.4, filed Dec. 13, 2018, the disclosures of which arehereby incorporated by reference in their entirety for all purposes.

TECHNICAL FIELD

The present invention relates to the field of pharmaceutical syntheses,and particularly to a compound that can serve as a novel agonist of THRβreceptors, and a preparation method and use thereof.

BACKGROUND

Thyroid hormone (TH) is synthesized in the thyroid gland in response tothe thyroid stimulating hormone (TSH) secreted by the pituitary.Thyroxine plays a rather important role in regulating body growth,development, metabolism, and body balance. Thyroid hormones mainlyinclude two types: 3,5,3′-triiodo-L-thyroxine (T3) and thyroxine (T4).Human bodies mainly secrete T4. In peripheral organs, T4 is transformedby deiodinase into T3 having greater activity. T3 and T4 produced by thethyroid gland are under negative feedback control. Thyrotropin (TSH) isresponsible for the normal thyroid function and thyroid hormonesecretion. Thyrotropin is synthesized in the anterior pituitary gland,and its secretion is controlled by the thyroid releasing hormone (TRH)synthesized in the hypothalamus.

Thyroid hormones function by binding to the thyroid hormone receptors(THR). The thyroid hormone receptor belongs to a family of nuclearreceptors and regulates the target gene expressions. Thyroid hormonereceptors include two different subtypes, i.e., THRα and THRβ. THRα ismainly distributed in cardiac tissues and plays an important role inregulating heart function. The THRfβ subtype is mainly expressed in theliver and the pituitary, and regulates cholesterol metabolism andthyrotropin secretion.

At normal levels, thyroid hormones THs maintain body weight, metabolicrate, body temperature, and mood, and are responsible for regulatingserum cholesterol. Attempts have been made to use thyroid hormones toregulate serum cholesterol. However, given the possible side effects onthe heart from taking natural thyroid hormone (e.g., tachycardia andarrhythmia, heart failure, and thyroid axis function, muscle metabolism,and osteoporosis,) thyroid hormones are unsuitable for treating highcholesterol and obesity. Research results regarding the study of animalswith selective knock-out of the THR gene, and research results of someselective THR ligands show that the side effects on the heart caused bythese thyroid hormones can be attributed to THRα.

The pathway of the thyroid hormone receptor regulates metabolism oflipids, including cholesterol, triglyceride, and lipoprotein. It hasbeen clinically shown that lowering the low-density cholesterol canreduce the incidence of cardiovascular diseases.

Non-alcoholic fatty liver disease (NAFLD) is also a type of metabolicdisorder disease caused by excessive accumulation of triglycerides inthe liver, which can further cause liver cell damage and inflammation,leading to non-alcoholic steatohepatitis (NASH). NASH patients usuallyhave type 2 diabetes, high cholesterol, hyperlipaemia, and obesity alongwith NASH. Furthermore, they are more likely to develop hepatocirrhosis,liver failure and, eventually, liver cancer. In the field, currentlydrugs that effectively treat NASH are limited. Given the thyroidhormone's function of regulating the lipid metabolism, the thyroidreceptor pathway becomes a potential target for the treatment of NASHand NAFLD. It has been proven in animal bodies that thyroid hormoneanalogues can significantly reduce fatty levels in animal livers.

Selective THRβ agonists can be used to avoid side effects on the heartthat result from conventional THR receptor agonists, and selectively toonly activate THRβ, thereby improving cell lipid metabolism, and achievethe function of lowering cholesterol and blood fat. However, selectiveTHRβ agonists may also inhibit the thyroid axis, leading to depression,fatigue, osteoporosis, and other side effects. Therefore, it is desiredto develop a selective THRβ agonist to activate THRβ, but to also reducethe inhibition of the thyroid axis, so as to avoid the side effectsaccompanying the thyroid axis inhibition.

Patents such as WO03094845, WO2007009913, WO2010122980, and WO2011038207reveal some THR receptor agonists. Structures of these agonists arealmost all designed and developed based on the natural ligand T3 of theTHR receptor. Based on such background, it is still desired to developselective THRβ receptor agonists which not only have the beneficialtherapeutic effects of thyroid hormones, but also avoid side effectsaffecting the heart.

Structural modification is carried out in the present invention also onthe basis of the natural ligand T3 of the THR receptor. The presentinventors unexpectedly found that, most of the modified compoundsmaintain good agonistic activity toward the THRβ receptor, and somecompounds also have improved selectivity toward THRα as compared withComparative compound 53 in the reference documents (“Discovery of2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile(MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist inClinical Trials for the Treatment of Dyslipidemia,” Martha et al.,Journal of Medicinal Chemistry, 2014, 3912-3923). At the same time, somecompounds of the present invention also show very desirablepharmacokinetic properties. The pharmacokinetic properties of somepreferred compounds are significantly better than those of thecomparative compound, thus improving the properties of the finisheddrug.

SUMMARY

In order to solve the above technical problem, the present inventionemploys the following technical solutions:

According to one aspect of the present invention, the present inventionprovides a compound represented by the following Formula (I) and apharmaceutically acceptable salt thereof,

-   -   wherein,    -   R₁ is selected from the group consisting of hydrogen, cyano,        substituted or unsubstituted C₁₋₆ alkyl, or substituted or        unsubstituted C₃₋₆ cycloalkyl, the substituent being selected        from the group consisting of halogen atoms, hydroxy, and C₁₋₆        alkoxy;    -   R₂ and R₃ are each independently selected from the group        consisting of halogen atoms or substituted or unsubstituted C₁₋₆        alkyl, the substituent being selected from the group consisting        of halogen atoms, hydroxy, and C₁₋₆ alkoxy;    -   ring A is a substituted or unsubstituted saturated or        unsaturated C₅₋₁₀ aliphatic ring, or a substituted or        unsubstituted C₅₋₁₀ aromatic ring, the substituent being one or        more substances selected from the group consisting of hydrogen,        halogen atoms, hydroxy, —OCF₃, —NH₂, —NHC₁₋₄ alkyl, —N(C₁₋₄        alkyl)₂, —CONH₂, —CONHC₁₋₄ alkyl, —CON(C₁₋₄ alkyl)₂, —NHCOC₁₋₄        alkyl, C₁₋₆ alkyl, C₁₋₆ alkoxy or C₃₋₆ cycloalkyl, and when two        substituents are contained, the two substituents can form a ring        structure together with the carbon connected thereto; and    -   the halogen atoms are selected from the group consisting of F,        Cl or Br.

The compound according to the present invention has a structure as shownin the following Formula (II):

-   -   wherein,    -   R₁ to R₃ are defined as described in the above Formula (I);    -   L is not present or is selected from the group consisting of        —CH₂— and —CH₂CH₂—;    -   R₄ is selected from the group consisting of hydrogen, halogen        atoms, hydroxy, —OCF₃, —NH₂, —NHC₁₋₄ alkyl, —N(C₁₋₄ alkyl)₂,        C₁₋₆ alkyl, C₁₋₆ alkoxy or C₃₋₆ cycloalkyl;    -   n is an integer from the range 1 to 4;    -   m is an integer from the range 1 to 4; and    -   when L is not present, the ring may have two or more        substituents R₄ thereon; and    -   the halogen atoms are selected from the group consisting of F,        Cl or Br.

Preferably, in the structure as shown in Formula (II), R₄ is selectedfrom the group consisting of

-   -   hydrogen, halogen atoms, hydroxy, C₁₋₃ alkyl, C₁₋₃ alkoxy or        C₃₋₆ cycloalkyl;    -   L is not present or is selected from the group consisting of        —CH₂— or —CH₂CH₂—;    -   n is 1, 2 or 3; and    -   m is 1 or 2.

Further preferably, in the structure as shown in Formula (II), R₄ isselected from the group consisting of hydrogen or C₁₋₃ alkyl;

-   -   L is —CH₂— or —CH₂CH₂—;    -   n is 1, 2 or 3; and    -   m is 1 or 2.

Further preferably, in the structure as shown in Formula (II), R₄ isselected from the group consisting of hydrogen or C₁₋₃ alkyl;

-   -   L is not present;    -   n is 1, 2 or 3; and    -   m is 1 or 2.

The compound according to the present invention has a structure as shownin the following Formula (III):

-   -   wherein,    -   R₁ to R₃ are defined as described in the above Formula (I);    -   R₄ is selected from the group consisting of hydrogen, halogen        atoms, hydroxy, —OCF₃, —NH₂, —NHC₁₋₄ alkyl, —N(C₁₋₄ alkyl)₂,        —CONH₂, —CONHC₁₋₄ alkyl, —CON(C₁₋₄ alkyl)₂, —NHCOC₁₋₄ alkyl,        C₁₋₆ alkyl, C₁₋₆ alkoxy or C₃₋₆ cycloalkyl;    -   m is an integer from the range 1 to 4; and    -   the halogen atoms are selected from the group consisting of F,        Cl or Br.

Preferably, in the structure as shown in Formula (III), R₄ is selectedfrom the group consisting of hydrogen, halogen atoms, hydroxy, —OCF₃,C₁₋₆ alkyl, C₁₋₆ alkoxy or C₃₋₆ cycloalkyl; and m is an integer from therange 1 to 3.

Preferably, in the structure as shown in Formula (III), R₄ is selectedfrom the group consisting of hydrogen, halogen atoms or C₁₋₃ alkyl; andm is 1 or 2.

Preferably, in the above compound having the structure of Formula (I),(II) or (III) according to the present invention, R₁ is selected fromthe group consisting of hydrogen, cyano, substituted or unsubstitutedC₁₋₆ alkyl; further preferably, R₁ is selected from the group consistingof cyano or C₁₋₃ alkyl; and still further preferably, R₁ is cyano.

Preferably, in the above compound having the structure of Formula (I),(II) or (III) according to the present invention, R₂ and R₃ are eachindependently selected from the group consisting of F, Cl or Br, andfurther preferably, both R₂ and R₃ are Cl.

Preferably, the compound and pharmaceutically acceptable salt thereofaccording to the invention are one of the following compounds:

According to another aspect of the present invention, the presentinvention provides a method for preparing the compound, the preparationmethod comprising the following steps:

-   -   1) reacting the internal anhydride compound I-a with hydrazine        hydrochloride, to obtain a compound of the general formula I-b;    -   2) heating the obtained compound of the general formula I-b in        phosphorus oxychloride, to form a compound of the general        formula I-c;    -   3) subjecting the obtained compound of the general formula I-c        and the compound I-d to coupling reaction at high temperature,        to obtain a compound of the general formula I-e, where the        catalyst at this condition is preferably cuprous iodide;    -   4) reacting the obtained compound of the general formula I-e at        acidic or alkaline high temperature, to obtain a compound of the        general formula I-f; and    -   5) reacting the obtained compound of the general formula I-f        with sodium nitrite in an aqueous acidic solution, followed by        the addition of a compound I-g for further reaction and ring        closing at high temperature, to obtain a compound of the general        formula I, where the acid is preferably hydrochloric acid under        this condition.

The compound of the general formula I according to the present inventionmay also be prepared as follows:

The compound of the general formula I-B-1 is subjected tohigh-temperature hydrolysis in an aqueous acidic solution, to obtain acompound of the general formula I-B-2, where the acid is preferablyhydrochloric acid under this condition; and the obtained compound of thegeneral formula I-B-2 is reacted in the presence of mercaptoacetic acidat a high temperature to eliminate carboxy, to obtain the compound ofthe general formula I.

The compound of the general formula I according to the present inventionmay also be prepared through the following method:

The compound of the general formula I-f is reacted with sodium nitriteunder an acidic condition, to form a diazonium salt compound, followedby the addition of a halide anion, to obtain a compound of the generalformula I-g; and under the catalysis of a transition metal, the obtainedcompound of the general formula I-g is coupled with the intermediateI-h, to obtain the compound of the general formula I.

According to another aspect of the present invention, the presentinvention provides use of the compound in the preparation of atherapeutic drug for a metabolism-related disease.

According to another aspect of the present invention, the presentinvention provides a pharmaceutical composition comprising atherapeutically effective amount of the compound according to thepresent invention and a pharmaceutically acceptable salt thereof as anactive ingredient, and a pharmaceutically acceptable adjuvant.

Preferably, the metabolism-related disease is selected from the groupconsisting of obesity, hyperlipidemia, hypercholesterolemia, diabetes,and non-alcoholic steatohepatitis (NASH), steatosis of liver,atherosclerosis, hypothyroidism, and thyroid cancer; and preferably, themetabolism-related disease is selected from the group consisting ofnon-alcoholic steatohepatitis (NASH), hypothyroidism and thyroid cancer.

According to another aspect of the present invention, the presentinvention provides a method for treating a metabolism-related disease,the method comprising administering to the subject an effective amountof the compound according to the present invention or a pharmaceuticalcomposition comprising the compound and pharmaceutically acceptable saltthereof as an active ingredient.

Preferably, according to the method for treating the metabolism-relateddisease, the metabolism-related disease is selected from the groupconsisting of: obesity, hyperlipidemia, hypercholesterolemia, diabetes,and non-alcoholic steatohepatitis (NASH), steatosis of liver,atherosclerosis, hypothyroidism, and thyroid cancer; and preferably, themetabolism-related disease is selected from the group consisting ofnon-alcoholic steatohepatitis (NASH), hypothyroidism and thyroid cancer.

DETAILED DESCRIPTION

The present invention is described below in detail. Prior to thedescription, it should be understood that, the terms used in thespecification and the appended claims shall not be interpreted to belimited to the general meaning and dictionary meaning, but shall beinterpreted according to the corresponding meaning and concepts in thetechnical aspects of the present invention on the basis of the principlethat the inventor is allowed to properly define the terms for the bestinterpretation. Therefore, the description proposed here is only apreferred example for the purpose of illustration, and is not intendedto limit the scope of the invention. Hence it should be understood thatother equivalents or improvements can be obtained from it withoutdeparting from the spirit and scope of the present invention.

According to the present invention, all terms quoted herein have thesame meaning as those skilled in the art that understand the invention,unless otherwise specified.

As used herein, the term “salt” refers to a compound containing cationsand anions, which can be formed by protonation of a site that can acceptprotons and/or proton abstraction of a site that can supply protons. Itis worth noting that the protonation of the site that can accept protonsleads to the formation of a cationic substance, and the charge thereofis balanced by the presence of physiological anions, whereas the protonabstraction of the site that can supply protons leads to the formationof an anionic substance, and the charge thereof is balanced by thepresence of physiological cations.

The term “pharmaceutically acceptable salt” refers that the salt ispharmaceutically acceptable. Examples of the pharmaceutically acceptablesalt include, but are not limited to: (1) acid addition salts, formedwith inorganic acid, e.g., hydrochloric acid, hydrobromic acid, sulfuricacid, nitric acid, and phosphoric acid; or formed with organic acid,e.g., glycolic acid, pyruvic acid, lactic acid, malonic acid, malicacid, maleic acid, fumaric acid, tartaric acid, citric acid,3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid,methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid,2-hydroxyethane sulfonic acid, benzene sulfonic acid,4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid,4-paratoluenesulfonic acid, camphoric acid, dodecylsulfuric acid,gluconic acid, glutamic acid, salicylic acid, and cis-muconic acid; or(2) alkali addition salts, formed with any conjugate base of the aboveinorganic acids, where the conjugate base comprises a cationic componentselected from the group consisting of Na⁺, K⁺, Mg²⁺, Ca²⁺, andNH_(x)R_(4−x) ⁺, where NH_(x)R_(4−x) ⁺ (R is C₁₋₄ alkyl, and thesubscript x is an an integer selected from the group consisting of 0, 1,2, 3 or 4) represents the cation in the quaternary ammonium salt. Itshould be understood that, all pharmaceutically acceptable saltsinvolved include the solvent addition form (solvate) or crystal form(polymorphic substance) as defined herein for the same acid additionsalt.

The term “C_(1-M) alkyl” refers to alkyl comprising 1 to M carbon atoms,e.g., where M is an integer having the following numerical value: 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29 or 30. For example, the term “C₁₋₆ alkyl”refers to alkyl containing 1 to 6 carbon atoms. Examples of alkylinclude, but are not limited to lower alkyl, including methyl, ethyl,propyl, i-propyl, n-butyl, i-butyl, t-butyl or amyl, i-amyl, neopentyl,hexyl, heptyl and octyl.

The term “aromatic group” refers to an aromatic system, which may be amonocyclic ring, or a poly-aromatic ring originally fused or joinedtogether such that at least a part of the fused or joined rings form aconjugated aromatic system. Aryl groups include, but are not limited to:phenyl, naphthyl and tetralyl. Aryl may be optionally substitutedby,e.g., 1 to 4 aryl groups or heterocyclic rings substituted by a groupselected from the group consisting of: halogen, —CN, —OH, —NO₂, amino,alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, aryloxy, substitutedalkoxy, alkylcarbonyl, alkylcarboxy, alkylamino, or arylthio.

The term “substitute” refers that the reference group can be substitutedby one or a plurality of additional groups, where the additional groupsare separately and independently selected from the group consisting ofalkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic hydrocarbon,hydroxy, alkoxy, alkylthiol, arylthio, alkylsulfinyl, arylsulfinyl,alkylsulfonyl, arylsulfonyl, cyano, halo, carbonyl, thiocarbonyl, nitro,haloalkyl, fluoroalkyl and amino, including monosubstituted anddisubstituted amino groups and derivatives protected by them.

The compound represented by Formula (I) or pharmaceutically acceptablesalt thereof provided by the present invention, and pharmaceuticalcompositions containing the compound may be in various forms, such astablets, capsules, powders, syrups, solutions, suspensions and aerosols,etc., and may exist in a suitable solid or liquid carrier or diluent,and in a disinfector suitable for injection or infusion.

Various dosage forms of the pharmaceutical composition of the presentinvention can be prepared according to preparation methods conventionalin the field of pharmacy. For example, the unit dose of the preparationformula contains 0.05 to 200 mg of the compound of Formula (I) orpharmaceutically acceptable salt thereof, and preferably, the unit doseof the preparation formula contains 0.1 to 100 mg of the compound ofFormula (I).

The compound represented by the general formula (I) or pharmaceuticalcompositions provided by the present invention can be used clinically inmammals, including humans and animals, through dosage routes such asoral, nasal, transdermal, transpulmonary or gastro-intestinal tractroutes. Oral administration is the most preferred. The most preferreddaily dose is 0.01 to 200 mg/kg of weight per single administration, or0.01 to 100 mg/kg of weight per separate administration. Regardless ofthe administration method, the best dose for an individual should bedecided on the basis of the specific treatment. Usually administrationstarts at a small dose and increases gradually until the most suitabledose is found.

In the present invention, the term “effective amount” may refer to theeffective amount for the dose and time period required to achieve theexpected effect. This effective dose may vary differently due to certainfactors, such as the disease type, symptoms of the disease at the timeof treatment; the structure of the specific target organ to beadministered; the individual height and weight of the patient, or theseverity of the disease or symptom. Those of ordinary skill in the artcan determine, by experience, the effective amount of a specificcompound without conducting unneeded experiments.

A typical formula is prepared by mixing the compound represented by thegeneral formula (I) of the invention, and a carrier, a diluent or anexcipient. Suitable carriers, diluents or excipients are well known tothose of skill in the art, including substances such as carbohydrates,waxes, water-soluble and/or expandable polymers, hydrophilic orhydrophobic substances, gelatin, oil, solvents, and water.

The specific carrier, diluent or excipient to be used shall be decidedaccording to the usage and purpose of the compound of the presentinvention. Generally, the solvent is selected on the basis of thesolvents which can be safely and effectively dosed to mammals accordingto those skilled in the art. In general, safe solvents are non-toxicaqueous solvents such as water and other non-toxic solvents that aresoluble in or miscible with water. Suitable aqueous solvents include oneor a plurality of water, ethanol, propylene glycol, polyethylene glycol(such as PEG400, and PEG300) and the like. The formula may also includeone or a plurality of buffers, stabilizers, surfactants, wetting agents,lubricants, emulsifiers, suspending agents, preservatives, antioxidants,light-screening agents, flow aids, processing aids, colorants,sweeteners, fragrances, flavoring agents or other known additives, toenable the drug to be manufactured or used in an acceptable form.

When the compound of Formula (I) of the present invention is used incombination with at least one other drug, the two or more drugs can beused separately or in combination, preferably in the form of apharmaceutical composition. The compound of Formula (I) or thepharmaceutical composition according to the present invention can bedosed to the subject separately or together, in any known oral,intravenous, rectal, vaginal, transdermal, other topical or systemicdosage forms.

These pharmaceutical compositions may also contain one or a plurality ofbuffers, stabilizers, surfactants, wetting agents, lubricants,emulsifiers, suspending agents, preservatives, antioxidants,light-screening agents, flow aids, processing aids, colorants,sweeteners, fragrances, flavoring agents, or other known additives, toenable the pharmaceutical compositions to be manufactured or used in anacceptable form.

The oral dosage route is preferred for the drug of the presentinvention. The solid dosage form for oral dosage may include capsules,tablets, powders or particle formulations. In the solid dosage form, thecompound or pharmaceutical composition according to the presentinvention is mixed with at least one inert excipient, diluent, orcarrier. Suitable excipients, diluents, or carriers include substancessuch as sodium citrate or dicalcium phosphate, or starch, lactose,sucrose, mannitol, silicic acid, and the like; adhesives such ascarboxymethyl cellulose, alginate, gelatin, polyvinyl pyrrolidone,sucrose, and Arabia gum; wetting agents such as glycerol; disintegratingagents such as agar, calcium carbonate, potato or cassava starch,alginic acid, specific complex silicate, and sodium carbonate; solutionblockers such as paraffin; absorption promoters such as quaternaryammonium compounds; adsorbents such as kaolin and bentonite; andlubricants such as talc, calcium stearate, magnesium stearate, solidpolyethylene glycol, and sodium lauryl sulfate. In the case of capsulesand tablets, the dosage form may also include buffers. Similar types ofsolid compositions may also be used as fillers in soft and hard filledgelatin capsules, which use lactose and high molecular weightpolyethylene glycol as excipients.

Liquid dosage forms for oral administration include pharmaceuticallyacceptable emulsions, solutions, suspensions, and syrups and elixirs. Inaddition to the compound or the pharmaceutical composition thereofaccording to the present invention, the liquid dosage form may containinert diluents commonly used in the art, such as water or othersolvents; solubilizers and emulsifiers such as ethanol, isopropylalcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzylbenzoate, propylene glycol, 1,3-butanediol, dimethylformamide; oils(e.g., cotton seed oil, peanut oil, corn germ oil, olive oil, castoroil, and sesame oil); glycerol; tetrahydrofurfuryl alcohol; fatty acidesters of polyethylene glycol and sorbitan; or mixtures of several ofthese substances, etc.

In addition to these inert diluents, the composition may also include anexcipient, such as one or a plurality of wetting agents, emulsifiers,suspending agents, sweeteners, flavoring agents, and fragrances.

In terms of the suspension, in addition to the compound represented bythe general formula (I) or pharmaceutically acceptable salt thereof orthe pharmaceutical composition comprising the same according to thepresent invention, the suspension may further contain carriers such assuspending agents, for example, ethoxylated isostearol, polyoxyethylenesorbitol, sorbitan ester, microcrystalline cellulose, aluminummetahydroxide, bentonite, agar and tragacanth gum, or mixtures ofseveral of these substances, etc.

The compound represented by the general formula (I) or apharmaceutically acceptable salt thereof or the pharmaceuticalcomposition comprising the same according to the present invention maybe dosed using other topical dosage forms, including ointments, powders,sprays and inhalants. This drug can be mixed under sterile conditionswith pharmaceutically acceptable excipients, diluents or carriers andany preservatives, buffers or propellants required. Ophthalmic formulae,ophthalmic ointments, powders, and solutions are also intended to beencompassed in the scope of the present invention.

In addition, the present disclosure further encompasses kits (e.g.,pharmaceutical packages). The kit provided may comprise thepharmaceutical composition or the compound described herein andcontainers (e.g., drug bottles, ampoules, bottles, syringes and/orsubpackages or other suitable containers). In some embodiments, the kitprovided may optionally further include a second container comprising apharmaceutical excipient for diluting or suspending the pharmaceuticalcomposition or the compound described herein. In some embodiments, thepharmaceutical composition or the compound described herein provided inthe first and the second containers are combined to form a unit dosageform.

In some embodiments, the kit described herein further includesinstructions of use of the compound or the pharmaceutical compositioncomprised in the kit. The kit described herein may also includeinformation required by regulatory agencies such as the US Food and DrugAdministration (FDA). In some embodiments, the information included inthe kit is formula information. In some embodiments, the kit and theinstructions are provided for the treatment of a proliferative diseasein subjects in need thereof and/or prevention of a proliferative diseaseof subjects in need thereof. The kit described herein may comprise oneor a plurality of additional pharmaceutical preparations as separatecompositions.

The present invention will be further described below in detail incombination with particular embodiments, but the present invention isnot limited to the following embodiments which serve the purpose ofbetter explaining specific embodiments of the present invention andshould not be interpreted as limiting the scope of the invention in anyway. The conditions not noted in the embodiments are conventionalconditions. Unless stated particularly, the reagents and apparatusesused in the following embodiments are all commercially availableproducts.

The structures of the compounds in the following embodiments aredetermined by nuclear magnetic resonance (NMR) or/and mass spectrometry(MS). The NMR displacement (δ) is given in the unit of 10-6 (ppm). Forthe determination by NMR, a Bruker AVANCE-400 nuclear magneticinstrument is used. Solvents are deuterated dimethyl sulfoxide(DMSO-d6), deuterated chloroform (CDC13) and deuterated methanol(CD3OD), and the internal standard is tetramethylsilane (TMS).

For determination by MS, a FINNIGAN LCQAd (ESI) mass spectrometer(manufacturer: Thermo, model: Finnigan LCQ advance max) is used.

Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates are used asthe silica gel plates for the thin-layer chromatography. Thespecification of the silica gel plate for the thin-layer chromatography(TLC) is 0.15 mm to 0.2 mm, and the specification for that in thethin-layer chromatography for separation and purification of products is0.4 mm to 0.5 mm.

Column chromatography generally uses Yantai Huanghai silica gel 200-300mesh silica gel as the carrier.

When no special description in the embodiments exists, the reactiontemperature is room temperature, i.e., 20° C. to 30° C.

The thin-layer chromatography (TLC) is employed to detect the reactionprocess in the embodiments. The developer system used and the eluentsystem of column chromatography employed for purifying the compoundinclude: A: a dichloromethane and methanol system; B: a n-hexane andethyl acetate system; C: a petroleum ether and ethyl acetate system; D:an acetone and petroleum ether system, where the ratio by volume of thesolvents is adjusted according to different polarities of the compounds.

Embodiment 1 Preparation of2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile

Step 1: Preparation of 2,3,5,6,7,8-hexahydrophthalazin-1,4-dione(Compound 1b)

Sodium acetate (3.69 g, 45 mmol) and hydrazine hydrochloride (3.08 g, 45mmol) were successively added into a solution of a compound3,4,5,6-tetrahydrophthalic anhydride 1a (4.56 g, 30 mmol) in acetic acid(50 ml) and water (100 ml). After the addition, the mixture was warmedup to a temperature of 100° C. and stirred for 3 h. The reaction wasstopped and naturally cooled to room temperature. A solid wasprecipitated and filtered out to obtain a compound 1b (4.2 g), and theproduct was directly used in the next reaction.

¹H NMR (400 MHz, DMSO-d₆): 11.26 (s, 2H), 2.36 (s,4H), 1.65(s, 4H).

Step 2: Preparation of 1,4-dichloro-5,6,7,8-tetrahydrophthalazine(Compound 1c)

The compound 1b (1 g, 6.02 mmol) was dissolved into phosphorusoxychloride (8 ml). The air in the system was replaced 3 times withnitrogen gas. The system was warmed up to a temperature of 110° C. andstirred for 3 h. The reaction was stopped and then naturally cooled. Thereaction solution was slowly dripped into ice water. The mixture wasadjusted to pH 10 with a 1N sodium hydroxide aqueous solution andextracted 3 times with ethyl acetate. Organic phases were combined, andthe organic phase was washed with saturated brine and concentrated todry, to obtain a compound 1c (1.1 g). The product was directly used inthe next reaction.

Step 3: Preparation of3,5-dichloro-4-((4-chloro-5,6,7,8-tetrahydrophthalazin-1-yl)oxy)aniline(Compound 1d)

Dimethyl sulfoxide (8 ml) was added into the mixture of the compound 1c(1.0 g, 5.0 mmol), 2,6-dichloro-4-aminophenol (0.93 g, 6 mmol),potassium carbonate (2.76 g, 20 mmol), and CuI (0.57 g, 3 mmol). The airin the system was replaced 3 times with nitrogen gas. The system waswarmed up to a temperature of 100° C. and stirred for 3 h. After thereaction was stopped, it was cooled. The solid in the reaction solutionwas filtered out first, and the filter residue was washed repeatedlywith ethyl acetate. 80 ml of water was added into the filtrate, and thenthe aqueous phase was extracted with ethyl acetate reaction. The organicphases were combined and washed with saturated brine. A compound 1d (450mg) was obtained by column chromatography after filtration and solventconcentration.

Step 4: Preparation of4-(4-amino-2,6-dichlorophenoxy)-5,6,7,8-tetrahydrophthalazin-1(2H)-one(Compound 1e)

The compound 1d (100 mg, 0.3 mmol) was dissolved into acetic acid (4ml), and sodium acetate (200 mg, 2.5 mmol) was added therein. Themixture was heated to a temperature of 120° C. and stirred for 12 h.After the reaction was stopped, the solvent was removed under reducedpressure. 10 ml of water was added therein, and then a 1N sodiumhydroxide aqueous solution was added to adjust the pH to 8. Thenextraction was carried out with ethyl acetate (10 ml×3), and organicphases were combined. The organic phase was washed with a saturatedaqueous sodium bicarbonate solution and saturated brine respectively,and concentrated under reduced pressure to obtain a gray solid. 10 ml ofmethanol and 10 ml of a 1N sodium hydroxide aqueous solution were addedinto the solid obtained, and the mixture was heated to a temperature of120° C. and stirred for 12 h. After the reaction was stopped, methanolwas concentrated under reduced pressure. The remaining aqueous phase wasextracted 3 times with ethyl acetate repeatedly, and organic phases werecombined. After the solvent was concentrated under reduced pressure,compound 1e (80 mg) was obtained by separation and purification throughthin-layer chromatography.

Step 5: Preparation of2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile(Compound 1)

Sodium nitrite (16 mg) was dissolved into water (0.5 mL). Under ice bathconditions, this solution was slowly added dropwise into a mixture of acompound 1e (60 mg, 0.185 mmol), water (2.5 mL) and a saturated aqueoushydrochloric acid solution (1.25 mL), and stirred for 0.5 h with the icebath conditions maintained, until the solution became clear. At thistemperature, a mixed solution of N-cyanoacetylurethane (32 mg) in water(4.2 ml) and pyridine (1.3 ml) was additionally added dropwise, andstirred overnight after the dropwise addition. After the reaction wasstopped, a yellow solid was filtered out, and washed with water andpetroleum ether. Acetic acid (5 ml) and sodium acetate (160 mg, 2 mmol)were added into the solid obtained. The mixture was heated to atemperature of 120° C. and stirred for 6 h, then cooled to roomtemperature. 100 ml of water was added therein to precipitate a lightyellow solid. After separation and purification through thin-layerchromatography (DCM:MeOH=8:1), compound 1 (12.0 mg) was obtained.

1H NMR (400 MHz, DMSO-d₆) δ 12.03 (s, 1H), 7.75 (s,2H), 2.68-2.63 (m,2H), 2.45-2.39 (m, 2H), 1.80-1.67 (m, 4H).

MS m/z (ESI): 447.4 [M+1].

Embodiment 2 Preparation of2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydro-5,8-ethanophthalazin-1-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile(Compound 2b)

The synthetic route of Embodiment 1 was employed, except that the rawmaterial 3,4,5,6-tetrahydrophthalic anhydride 1a in Step 1 was replacedwith bicyclo[2.2.2]oct-2-ene-2,3-dicarboxylic anhydride, to produce thetitle product2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydro-5,8-ethanophthalazin-1-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile (compound 2).

¹H NMR (400 MHz, DMSO-d₆): 12.13 (s, 1H), 7.77 (s,2H), 1.88-1.73 (m,4H), 1.39-1.17 (m, 6H).

MS m/z (ESI): 473.2 [M+1].

Embodiment 3 Preparation of2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydro-5,8-methanophthalazin-1-yl)oxo)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile(Compound 3)

Step 1: Preparation ofdimethyl-bicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate

Dimethyl acetylenedicarboxylate (compound 3b) (2.75 ml, 22.3 mmol) wasslowly dripped into cyclopentadiene (compound 3a) (1.475 g, 22.3 mmol),and stirred for 2 h at room temperature after the addition. The reactionwas stopped, and an oily product 3c (4.0 g) was obtained. The crudeproduct was directly used in the next reaction without purification.

Step 2: Preparation ofdimethyl-bicyclo[2.2.1]hepta-2-ene-2,3-dicarboxylate

The compound 3c (1.0 g,4.8 mmol), palladium carbon (0.05 g) and 15 ml ofacetone were placed into a reaction flask, and replacement was performed3 times under a hydrogen balloon. The system was stirred for 1 h at roomtemperature. Filtration was carried out, and the solvent wasconcentrated to dry under reduced pressure, to obtain a light greenliquid product 3d (0.9 g).

Step 3: Preparation of bicyclo[2.2.1]hepta-2-ene-2,3-diacid

Tetrahydrofuran (20 ml) and water (20 ml) were added into a mixture ofthe compound 3d (3.0 g, 14.3 mmol) and lithium hydroxide monohydrate(1.54 g, 35.8 mmol), and stirred for 2 h at room temperature. Thesolution was adjusted to pH 1 with 2N dilute hydrochloric acid,extracted 3 times with ethyl acetate, dried over anhydrous sodiumsulfate, filtered, and concentrated under reduced pressure to obtain awhite solid compound 3e (2.0 g).

Step 4: Preparation of4,5,6,7-tetrahydro-4,7-methanoisophenylfuran1,3-dione

Acetic anhydride (10 mL) was added into the compound 3e (200 mg, 1.1mmol). The mixture was heated to a temperature of 100° C. and stirredfor 2 h. The solvent was removed by concentration under reducedpressure, to obtain a crude product of a solid compound 3f (200 mg).

Step 5: Preparation of2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydro-5,8-methanophthalazin-1-yl)oxo)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile

The synthetic route of Embodiment 1 was employed, except that the rawmaterial 4,5,6,7-tetrahydroisobenzofuran-1,3-dione (compound 1a) in Step1 was replaced with 4,5,6,7-tetrahydro-4,7-methanoisophenylfuran1,3-dione (compound 3f), to produce the title product2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydro-5,8-methanophthalazin-1-yl)oxo)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile(compound 3).

¹H NMR (400 MHz, DMSO-d₆) δ 12.08 (s, 1H), 7.77 (s,2H), 2.75-2.65 (m,2H), 1.80-1.72 (m, 4H), 1.55-1.50 (m, 2H).

MS m/z (ESI): 459.0 [M+1].

Embodiment 4 Preparation of1-(3,5-dihcloro-4-((7,7-dimethyl-1-oxo-2,5,6,7-tetrahydro-1H-cyclopentane[d]pyridazin-4-yl)oxy)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-nitrile(Compound 4)

Step 1: Preparation of methyl3,3-dimethyl-2-oxocyclopentyl-1-carboxylate

NAH (480 mg, 12 mmol) was added into a solution of a compound2,2-dimethylcyclopentane-1-one (1.12 g, 10 mmol) and MeOH (0.5 ml) inDMC (11 ml). The mixture was heated to a temperature of 82° C., stirredfor 3 h, and cooled. Methanol (0.5 ml) and acetic acid (1 ml) weresuccessively added into the system, then the system was poured into icewater, extracted with dichloromethane, dried, and subjected to removalof the solvent under reduced pressure, to obtain a colorless oilycompound 4a (1.7 g) directly used in the next step.

Step 2: Preparation of methyl3,3-dimethyl-2-(((trifluoromethyl)sulfo)oxo)cyclopent-1-ene-1-carboxylate

At −60° C., trifluoroacetic anhydride (2 ml, 12 mmol) was added dropwiseinto a solution of the compound 4a (1.7 g, 10 mmol) anddiisopropylethylamine (8.2 ml, 50 mmol) in dichloromethane (17 ml).After the addition, the mixture was slowly warmed up to room temperatureand stirred for 16 h. 50 ml of water was added therein, and the mixturewas extracted with ethyl acetate, subjected to removal of the solventunder reduced pressure, and purified through column chromatography(PE:EA=50:1), to obtain a colorless oily compound 4b (1.8 g).

Step 3: Preparation of2-(methoxycarbonyl)-5,5-dimethylcyclopent-1-ene-1-carboxylic acid

Under the atmosphere of a nitrogen gas balloon, DMF (25 ml) was addedinto a mixture of 4b (1.8 g, 5.96 mmol), diisopropylethylamine (1.97 ml,11.92 mmol), acetic anhydride (1.13 ml, 11.92 mmol), sodium formate(1.22 g, 5.96 mmol), palladium diacetate (66.9 mg, 0.30 mmol), andlithium chloride (758 mg, 17.88 mmol). The system was stirred for 16 hat room temperature after the addition, and 300 ml of ethyl acetate wasadded into the system. The system was washed with water and saturatedbrine once each. The solvent was removed under reduced pressure, toobtain a colorless oil 4c (1.2 g).

Step 4: Preparation of 3,3-dimethylcyclopent-1-ene-1,2-dicarboxylic acid

Methanol (6 ml) and water (6 ml) were added into a mixture of 4c (1.2 g,6 mmol) and lithium hydroxide monohydrate (756 mg, 18 mmol), and stirredfor 3 h at room temperature. Methanol was removed under reducedpressure, then the solution was adjusted to pH 1 with concentratedhydrochloric acid and extracted with ethyl acetate, and the solvent wasremoved under reduced pressure, to obtain a white solid compound 4d (1.0g).

Step 5: Preparation of4,4-dimethyl-5,6-dihydro-1H-cyclopentyl[c]furan-1,3(4H)-dione

Acetic anhydride (10 ml) was added into the compound 4d (1.0 g, 5.43mmol). The mixture was warmed up to a temperature of 100° C., stirredfor 3 h, and cooled. Superfluous acetic anhydride was removed underreduced pressure, to obtain a light brown liquid compound 4e (875 mg),which was directly used in the next synthesis.

Step 6: Preparation of1-(3,5-dichloro-4-((7,7-dimethyl-1-oxo-2,5,6,7-tetrahydro-1H-cyclopentane[d]pyridazin-4-yl)oxy)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-nitrile

The synthetic route of Embodiment 1 was employed, except that the rawmaterial 3,4,5,6,-tetrahydrophthalic anhydride (compound 1a) in Step 1was replaced with4,4-dimethyl-5,6-dihydro-1H-cyclopentyl[c]furan-1,3(4H)-dione (compound4e), to produce the title product1-(3,5-dichloro-4-((7,7-dimethyl-1-oxo-2,5,6,7-tetrahydro-1H-cyclopentane[d]pyridazin-4-yl)oxy)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-nitrile(compound 4).

¹H NMR (400 MHz, DMSO-d₆) δ12.09 (s, 1H), 7.79 (s,2H), 2.97-2.93 (m,2H), 2.01-1.98 (m, 2H), 1.34-1.20 (m, 6H).

MS m/z (ESI): 460.9 [M+1].

Embodiment 5 Preparation of1-(3,5-dichloro-4-((5-methyl-4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)oxo)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-nitrile(Compound 5)

Step 1: Preparation of methyl 3-methyl-2-oxocyclohexane-1-carboxylate 5b

NaH (60% content, 1.92 g, 48 mmol) was added into a solution of2-methylcyclohexanone (compound 5a) (4.48 g, 40 mmol) in dichloromethane(50 ml). The mixture was heated to reflux, stirred for 3 h, and cooled.The mixture was roughly quenched with methanol (0.5 ml) and acetic acid(1 ml). The reaction system was added into an ice bath and extractedwith dichloromethane. The solvent was removed under reduced pressure,and an oil (compound 5b) (5.6 g) was obtained by purification throughcolumn chromatography.

Step 2: Preparation of methyl3-methyl-2-(((trifluoromethyl)sulfo)oxo)cyclohexyl-1-ene-1-carboxylate

Under ice bath conditions, NaH (60% content, 600 mg, 25 mmol) was addedinto compound 5b (0.85 g, 5 mmol) in ethyl ether (20 ml), and stirredfor 0.5 h. Then trifluoromethanesulfonic anhydride (2.8 g, 10 mmol) wasadded dropwise into the system and further stirred for 1 h at atemperature of 0° C. The system was quenched with H₂O (50 ml) added,adjusted to pH 1 with 1N HCl added, and extracted with dichloromethane.The solvent was removed under reduced pressure, and a colorless oilycompound 5c (1.04 g) was obtained by purification through columnchromatography (PE:EA=20:1).

Step 3: Preparation of2-(methoxycarbonyl)-6-methylcyclohexyl-1-ene-1-carboxylic acid

Under a nitrogen atmosphere, diisopropylethylamine (0.714 g, 7.00 mmol)and acetic anhydride (0.903 g, 7.00 mmol) were successively addeddropwise into a solution of the compound 5c (0.714 g, 10.5 mmol) andsodium formate (0.714 g, 10.50 mmol) in N,N-dimethyl formamide (15 ml),and stirred for 1 h at room temperature. Then palladium acetate (40 mg,0.18 mmol) and lithium chloride (445 mg, 10.50 mmol) were added, and thesystem was stirred overnight at room temperature. Ethyl acetate (30 ml)was added therein, and the mixture was washed with water. The solventwas removed under reduced pressure, to obtain a light yellow oilycompound 5d (590 mg).

Step 4: Preparation of 3-methylcyclohexyl-1-ene-1,2-diacid 5e

Lithium hydroxide monohydrate (0.375 g, 8.94 mmol) was added into asolution of the compound 5d (0.590 g, 2.98 mmol) in methanol (3 ml) andwater (3 ml), and stirred for 3 h at room temperature. Then methanol wasremoved under reduced pressure. The system was adjusted to pH 1 with a1N aqueous hydrochloric acid solution added, and extracted 3 times withethyl acetate. The organic phases were combined, and concentrated underreduced pressure to remove the solvent, to obtain an oily compound 5e(0.550 g).

Step 5: Preparation of 4-methyl-4,5,6,7-tetrahydroisophenylfuran-1,3-dione 5f

Acetic anhydride (6 ml) was added into the compound 5e (0.550 g, 2.99mmol). The mixture was warmed up to a temperature of 100° C., andstirred for 2 h. The system was cooled, and the solvent was removedunder reduced pressure, to obtain a brown oily compound 5f (0.34 g)directly used in the next synthesis.

Step 6: Preparation of1-(3,5-dichloro-4-((5-methyl-4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)oxo)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-nitrile(Compound 5)

The synthetic route of Embodiment 1 was employed, except that the rawmaterial 3,4,5,6,-tetrahydrophthalic anhydride (compound 1a) in Step 1was replaced with 4-methyl-4,5,6,7-tetrahydroisophenylfuran-1,3-dione(compound 5f), to produce the title product1-(3,5-dichloro-4-((5-methyl-4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)oxo)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-nitrile(compound 5).

MS m/z (ESI): 460.1 [M+1]

Embodiment 6 Preparation of1-(3,5-dichloro-4-((5,5-dimethyl-4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)oxo)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-nitrile

The synthetic route of Embodiment 5 was employed, except that the rawmaterial 2-methylcyclohexanone (compound 5a) in Step 1 was replaced with2,2-dimethylcyclohexanone, to produce the title product1-(3,5-dichloro-4-((5,5-dimethyl-4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)oxo)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-nitrile(compound 6).

MS m/z (ESI): 474.1 [M+1]

Embodiment 7 Preparation of1-(3,5-dichloro-4-((7-methyl-1-oxo-2,5,6,7-tetrahydro-1H-cyclopentyl[d]pyridazin-4-yl)oxo)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-nitrile(Compound 7)

The synthetic route of Embodiment 5 was employed, except that the rawmaterial 2-methylcyclohexanone (compound 5a) in Step 1 was replaced with2-methylcyclopentanone, to produce the title product1-(3,5-dichloro-4-((7-methyl-1-oxo-2,5,6,7-tetrahydro-1H-cyclopentyl[d]pyridazin-4-yl)oxo)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-nitrile(compound 7).

MS m/z (ESI): 446.0 [M+1]

Embodiment 8 Preparation of1-(3,5-dichloro-4-((7-ethyl-1-oxo-2,5,6,7-tetrahydro-1H-cyclopentane[d]pyridazin-4-yl)oxo)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-nitrile(Compound 8)

The synthetic route of Embodiment 5 was employed, except that the rawmaterial 2-methylcyclohexanone (compound 5a) in Step 1 was replaced with2-ethylcyclopentanone, to produce the title product1-(3,5-dichloro-4-((7-ethyl-1-oxo-2,5,6,7-tetrahydro-1H-cyclopentane[d]pyridazin-4-yl)oxo)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-nitrile(compound 8).

MS m/z (ESI): 460.1 [M+1]

Embodiment 9 Preparation of2-(3,5-dichloro-4-((4-oxo-3,4-dihydrophthalazin-1-yl)oxo)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile(Compound 9)

The synthetic route of Embodiment 1 was employed, except that the rawmaterial 1,4-dichloro-5,6,7,8-tetrahydrophthalazine (compound 1c) inStep 3 was replaced with 1,4-dichlorophthalazine, to produce the titleproduct2-(3,5-dichloro-4-((4-oxo-3,4-dihydrophthalazin-1-yl)oxo)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile(compound 9).

¹H NMR (400 MHz, DMSO-d₆): 12.00 (s, 1H), 8.31 (d, J=8.0 Hz, 1H), 8.26(d, J=8.0 Hz, 1H), 8.09 (t, J=12.0 Hz 1H), 8.03 (t, J=16.0 Hz 1H), 7.81(s, 2H).

MS m/z (ESI): 443.0 [M+1].

Embodiment 10 Preparation of2-(3,5-dichloro-4-((5-chloro-4-oxo-3,4-dihydrophthalazin-1-yl)oxo)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile(Compound 10)

The synthetic route of Embodiment 1 was employed, except that the rawmaterial 3,4,5,6,-tetrahydrophthalic anhydride (compound 1a) in Step 1was replaced with 3-chlorophthalic anhydride, to produce the titleproduct 2-(3,5-dichloro-4-((5-chloro-4-oxo-3,4-dihydrophthalazin-1-yl)oxo)phenyl)-3,5 -dioxo-2,3,4,5-tetrahy dro-1,2,4-triazine-6-nitrile(compound 10)

1H NMR (400 MHz, DMSO-d₆): 12.00 (s, 1H), 8.30 (d, J=8.0 Hz, 1H), 8.15(d, J=8.0 Hz, 1H), 7.95 (m, 1H), 7.80 (s, 2H).

MS m/z (ESI): 477.0 [M+1].

Embodiment 11 Preparation of2-(3,5-dichloro-4-((5-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)oxo)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile(Compound 11)

The synthetic route of Embodiment 1 was employed, except that the rawmaterial 3,4,5,6,-tetrahydrophthalic anhydride (compound 1a) in Step 1was replaced with 3-methylphthalic anhydride, to produce the titleproduct2-(3,5-dichloro-4-((5-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)oxo)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile(compound 11).

MS m/z (ESI): 456.9 [M+1].

Embodiment 12 Preparation of2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydro-5,8-ethanophthalazin-1-yl)oxo)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(Compound 12)

Step 1: Preparation of2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydro-5,8-ethanophthalazin-1-yl)oxo)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylicacid

Acetic acid (4 ml) and concentrated hydrochloric acid (1 ml) wererespectively added into the compound 2 (77 mg), heated to a temperatureof 120° C., stirred for 5 h, and cooled. The reaction solution wasdiluted with water. The solid obtained was filtered, washed with water,and washed with petroleum ether, to obtain a solid compound 12a (35 mg)directly used in the next reaction.

Step 2: Preparation of2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydro-5,8-ethanophthalazin-1-yl)oxo)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione

Mercaptoacetic acid (2 ml) was added into the compound 12a (35.0 mg),and the mixture was heated to a temperature of 170° C. and stirred for 2h. The mixture was cooled, adjusted to pH 8 with a 1N aqueous sodiumhydroxide solution, and extracted 3 times with ethyl acetate. Organicphases were combined. The solvent was removed under reduced pressure,and a compound 12 (10.0 mg) was obtained by separation and purificationthrough thin-layer chromatography (DCM:MeOH=8:1).

¹H NMR (400 MHz, DMSO-d₆): 12.10 (s, 1H), 7.77 (s, 2H), 7.33 (s, 1H),2.01 (m, 2H), 1.93-1.75 (m, 4H), 1.39-1.27 (m, 4H).

MS m/z (ESI): 448.0 [M+1].

Embodiment 13 Preparation of2-(3,5-dichloro-4-((7,7-dimethyl-1-oxo-2,5,6,7-tetrahydro-1H-cyclopentyl[d]pyridazin-4-yl)oxo)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(Compound 13)

The synthetic route of Embodiment 12 was employed, except that the rawmaterial2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydro-5,8-ethanophthalazin-l-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile(compound 2) in Step 1 was replaced with1-(3,5-dichloro-4-((7,7-dimethyl-l-oxo-2,5,6,7-tetrahydro-1H-cyclopentane[d]pyridazin-4-yl)oxy)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-nitrile(compound 4), to produce the title product2-(3,5-dichloro-4-((7,7-dimethyl-l-oxo-2,5,6,7-tetrahydro-1H-cyclopentyl[d]pyridazin-4-yl)oxo)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(compound 13).

¹H NMR (400 MHz, DMSO-d₆): 12.02 (s, 1H), 7.77 (s, 2H), 7.35 (s, 1H),2.94-2.90 (m, 2H), 1.99-1.95 (m, 2H), 1.32 (d, 6H).

MS m/z (ESI): 436.0 [M+1].

Embodiment 14 Preparation of2-(3,5-dichloro-4-((4-oxo-3,4-dihydrophthalazin-1-yl)oxo)phenyl)-1,2,4-triazine-3,5-(2H,4H)dione(Compound 14)

The synthetic route of Embodiment 12 was employed, except that the rawmaterial2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydro-5,8-ethanophthalazin-1-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile(compound 2) in Step 1 was replaced with2-(3,5-dichloro-4-((4-oxo-3,4-dihydrophthalazin-1-yl)oxo)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile (compound 9), to produce the titleproduct2-(3,5-dichloro-4-((4-oxo-3,4-dihydrophthalazin-1-yl)oxo)phenyl)-1,2,4-triazine-3,5-(2H,4H)dione(compound 14).

1H NMR (400 MHz, DMSO-d₆): 12.00 (s, 1H), 8.30-8.23 (m, 2H), 8.09-7.99(m, 2H), 7.18 (s, 1H).

MS m/z (ESI): 418.0 [M+1].

Embodiment 15 Preparation of2-(3,5-dichloro-4-((5-fluoro-4-oxo-3,4-dihydrophthalazin-1-yl)oxo)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile(Compound 15)

The synthetic route of Embodiment 1 was employed, except that the rawmaterial 3,4,5,6,-tetrahydrophthalic anhydride (compound 1a) in Step 1was replaced with 3-fluorophthalic anhydride, to produce the titleproduct2-(3,5-dichloro-4-((5-fluoro-4-oxo-3,4-dihydrophthalazin-1-yl)oxo)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile(compound 15).

MS m/z (ESI): 461.0 [M+1].

Embodiment 16 Preparation of2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)oxo)phenyl)-6-methyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 16)

Step 1: Preparation of4-(2,6-dichloro-4-iodophenoxy)-5,6,7,8-tetrahydrophthalazin-1(2H)-one(compound 16a)

Under ice bath conditions, water (4 ml) and concentrated hydrochloricacid (2 ml) were successively added into 1e (100 mg), followed by thedropwise addition of a solution of sodium nitrite (30 mg) in water (2ml). The reaction was stirred for 1 h under the maintained ice bathconditions. Potassium iodide (104 mg) was added dropwise, and themixture was warmed up to room temperature and stirred for 16 h. Themixture was extracted with dichloromethane, and the solvent was removedunder reduced pressure, to obtain a yellow solid 16a (100 mg), directlyused in the next reaction.

Step 2: Preparation of2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)oxo)phenyl)-6-methyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 16)

N,N-dicarbonamide (2.0 ml) was added into a mixture of the compound 16a(20 mg), 6-azathymine (6.6 mg), cuprous iodide (8.9 mg), and potassiumcarbonate (30 mg), and the system was heated to a temperature of 120° C.and stirred for 12 h. The system was cooled, filtered, and separatedfrom water through the addition of ethyl acetate. The solvent wasremoved from the organic phase under reduced pressure, and a compound 16(5.0 mg) was obtained by separation and purification through thin-layerchromatography (DCM:MeOH=8:1).

MS m/z (ESI): 436.1 [M+1].

Embodiment 17 Preparation of2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)oxo)phenyl)-6-isopropyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 17)

The synthetic route of Embodiment 16 was employed, except that the rawmaterial 6-azathymine in Step 2 was replaced with6-isopropyl-1,2,4-triazine-3,5(2H,4H)-dione (prepared by employing thewell known method “Chemistry and Biodiversity, 2012, 9(3) 536-556”), toproduce the title product2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)oxo)phenyl)-6-isopropyl-1,2,4-triazine-3,5(2H,4H)-dione(compound 17).

MS m/z (ESI): 464.1 [M+1].

Embodiment 18 Preparation of6-cyclopropyl-2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)oxo)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione(Compound 18)

The synthetic route of Embodiment 16 was employed, except that the rawmaterial 6-azathymine in Step 2 was replaced with6-cyclopropyl-1,2,4-triazine-3,5(2H,4H)-dione (prepared by employing thewell known method found in “Collection of Czechoslovak ChemicalCommunications, 1975, 40, 1038-1041”), to produce the title product2-(3,5-dichloro-4-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)oxo)phenyl)-6-cyclopropyl-1,2,4-triazine-3,5(2H,4H)-dione(compound 18).

MS m/z (ESI): 462.1 [M+1].

Embodiment 19 Preparation of2-(3,5-dichloro-4-((4-oxo-3,4-dihydrophthalazin-1-yl)oxo)phenyl)-6-methyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 19)

Step 1: Preparation of3,5-dichloro-4-((4-chlorophthalazin-1-yl)oxo)aniline (Compound 19a)

The synthetic route of Intermediate 1d in Step 3 of Embodiment 1 wasemployed, except that 1,4-dichloro-5,6,7,8-tetrahydrophthalazine(compound 1c) was replaced with 1,4-dichlorophthalazine, to produce thetitle product 3,5-dichloro-4-((4-chlorophthalazin-1-yl)oxo)aniline(compound 19a).

Step 2: Preparation of4-(4-amino-2,6-dichlorophenoxy)phthalazin-1(2H)-one (Compound 19b)

The synthetic route of Intermediate 1e in Step 4 of Embodiment 1 wasemployed, except that3,5-dichloro-4-((4-chloro-5,6,7,8-tetrahydrophthalazin-1-yl)oxy)aniline(compound 1d) was replaced with3,5-dichloro-4-((4-chlorophthalazin-1-yl)oxo)aniline (compound 19a), toproduce the title product4-(4-amino-2,6-dichlorophenoxy)phthalazin-1(2H)-one (compound 19b).

Step 3: Preparation of2-(3,5-dichloro-4-((4-oxo-3,4-dihydrophthalazin-1-yl)oxo)phenyl)-6-methyl-1,2,4-triazine-3,5(2H,4H)-dione(Compound 19)

The synthetic route of Embodiment 16 was employed, except that4-(2,6-dichloro-4-iodophenoxy)-5,6,7,8-tetrahydrophthalazin-1(2H)-one(compound 16a) in Step 1 was replaced with the compound4-(4-amino-2,6-dichlorophenoxy)phthalazin-1(2H)-one (compound 19b), toproduce the title product2-(3,5-dichloro-4-((4-oxo-3,4-dihydrophthalazin-1-yl)oxo)phenyl)-6-methyl-1,2,4-triazine-3,5(2H,4H)-dione(compound 19).

MS m/z (ESI): 432.0 [M+1].

Embodiment 20 Preparation of2-(3,5-dichloro-4-((6-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile(Compound 20):

The synthetic route of Embodiment 1 was employed, except that the rawmaterial tetrahydrophthalic anhydride (1a) in Step 1 was replaced with4-methylphthalic anhydride, to produce the title product2-(3,5-dichloro-4-((6-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile(compound 20).

MS m/z (ESI): 457.0 [M+1].

Embodiment 21 Preparation of2-(3,5-dichloro-4-((6-chloro-4-oxo-3,4-dihydrophthalazin-1-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile(Compound 21)

The synthetic route of Embodiment 1 was employed, except that the rawmaterial tetrahydrophthalic anhydride (1a) in Step 1 was replaced with4-chlorophthalic anhydride, to produce the title product2-(3,5-dichloro-4-((6-chloro-4-oxo-3,4-dihydrophthalazin-1-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile(compound 21).

MS m/z (ESI): 477.0 [M+1].

Test Embodiment 1 Binding Force of the Compound to TRα Test

1. Main Experimental Materials and Apparatuses:

-   -   Envision 2104 microplate reader;    -   Biotin-SRC2-2 coactivator peptide, commercially available from        Sangon Biotech (Shanghai) Co., Ltd.;    -   TRα LBD, GST, commercially available from ThermoFisher (Art. No.        PV4762);    -   Europium binding anti-glutathione antibody, commercially        available from Cisbio (Art. No. 61GSTKLB); and    -   Streptavidin-D2, commercially available from Cisbio (Art. No.        610SADAB)

2. Preparation and Treatment of Compounds

2.1 Preparation of Stock Solution of the Compound in Dimethyl Sulfoxide

All compounds were dissolved in dimethyl sulfoxide to prepare a 10 mmolstock solution.

2.2 Compound Storage

After the compounds were dissolved in dimethyl sulfoxide, the solutioncan be stored for 3 months in a desiccator at room temperature. Forlong-term storage, compounds shall be placed into a refrigerator at −20°C.

3. Experimental Steps

3.1 Preparation of 1× Reaction Buffer

3.2 Compound Screening:

-   -   a) 100% dimethyl sulfoxide was used to dilute the positive drug        triiodothyronine (T3) from 10 mmol (100×) or the compound to be        tested from 1 mmol (100×), at an equal ratio of 1:3, for a total        of 10 concentrations.    -   b) a 4× concentration gradient diluted compound was prepared        with a 1× reaction buffer.    -   c) 5 μl of the 4× concentration gradient diluted compound was        added into a 384-well test plate.    -   d) 4×TRα LBD and 4×RXRα were prepared with the 1× reaction        buffer.    -   e) 5 μl of 4×TRα LBD and 4×RXRα were added into the 384-well        test plate.    -   f) 2× biotin-SRC2-2, 2× Europium binding anti-glutathione        antibody, and 2× streptavidin-d2 were prepared with the 1×        reaction buffer.    -   g) 10 μl of a 2× mixed solution (referring to Step f) was added        into the 384-well test plate.    -   h) The 384-well test plate was centrifugated for 1000        revolutions within 1 min in a centrifuge.    -   i) Incubation at room temperature was performed for 1 h while        protected from light.    -   j) The fluorescence signal values of each well of the 384-well        test plate at the wavelength of 665 nm and 615 nm were recorded        with the Envision 2104 microplate reader, and the fluorescence        ratio of 665 nm/615 nm was calculated.

4. Data Analysis

4.1 Calculation of Relative Ratio (ratio_(665 nm/615 nm)-ratio_(blank))of each Well

4.2 The Activity Percentage was Calculated as Follows:

${{Activity}(\%)} = {\left\lfloor \frac{{Ratio}_{compound} - {\overset{\_}{Ratio}}_{blank}}{{\overset{\_}{Ratio}}_{positive} - {\overset{\_}{Ratio}}_{blank}} \right\rfloor*100}$

-   -   Ratio _(compound): average of relative ratios of wells of        embodiment compounds    -   Ratio _(positive): average of relative ratios of all positive        control wells    -   Ratio _(blank): average of relative ratios of all negative        control wells

4.3 Curve Plotting and EC50 Calculation:

-   -   EC50 was calculated by using Graphpad 5.0 through the nonlinear        regression method to fit the relationship between the activity        (%) and the logarithm concentration of the compound.

Y=bottom+(top−bottom)/(1+10{circumflex over ( )}((Log EC50−X)×slope))

-   -   X: Logarithm concentration of the compound Y: Percentage        activity    -   Particular test data are shown in Table 1 as follows.

Test Embodiment 2 Evaluation of the Agonistic Activity of the Compoundtoward TRα

1. Main Experimental Materials and Apparatuses:

-   -   Envision 2104 microplate reader    -   HEK293T cell line, commercially available from ATCC (Art. No.:        CRL-3216)    -   pGL4.35[luc2P/9XGAL4 UAS/Hygro], commercially available from        Promega (Art. No.: E1370)    -   pBIND-TRα plasmid, from Pharmaron

pBIND-RXRα plasmid, from Pharmaron

-   -   LipoLTX transfection agent, commercially available from        ThermoFisher (Art. No.: 15338-100)

2. Compound Preparation

2.1 Compound Dissolution

The compound powder was prepared into a 10 mmol stock solution indimethyl sulfoxide according to the standard scheme.

2.2 Compound Storage

All compounds dissolved in dimethyl sulfoxide were stored in adesiccator at room temperature for a short term, or stored at −20° C.for a long term.

2.3 Preparation of Experimental Compounds

-   -   2.3.1 All the compounds to be tested were diluted with dimethyl        sulfoxide at a 3-fold gradient, in 10 dilution gradients,        starting from the initial concentration of 10 μmol.    -   2.3.2 The positive control triiodothyronine (T3) was diluted        with dimethyl sulfoxide at a 3-fold gradient, in 10 dilution        gradients, starting from the initial concentration of 16.67        μmol.    -   2.3.3 A 166.7×positive control (16.67 μmol, triiodothyronine        (T3)) and a 166.733 negative control (100% dimethyl sulfoxide)        were prepared.

2.4 The compound plate was closed and shaken for 5 min.

3 Experiment Process

3.1 Cell Suspension Preparation and Plate Seeding

-   -   a) All cells were cultured according to the ATCC standard        operation, and HEK293T was tested in the exponential growth        period;    -   b) The medium was discarded;    -   c) The cells were washed twice with a phosphate buffer;    -   d) A trypsinization solution was added to digest the cells, and        the digestion was terminated with a complete medium;    -   e) The cells were collected and counted, and only when the cell        viability was greater than 90% could the experiment be carried        out;    -   f) 2.5×10⁶ HEK293-LUC cells were seeded into a 60-mm cell        culture dish; and    -   g) The culture dish with cells seeded was placed into an        incubator at 37° C. and 5% CO₂ and cultured overnight.

3.2 Cell Transfection

-   -   a) The LipoLTX transfection agent was placed at room temperature        for balancing;    -   b) 6 μl of Plus agent and 6 μg of DNA were added into 250 μl of        Opti-MEM™ medium without contacting the tube wall, and they were        mixed uniformly through blowing and pipetting by a pipetting        gun, and    -   Plasmid: 2.5 μg of pBIND-TRα, 2.5 μg of pBIND-RXRα and 1 μg of        pGL4.35 plasmid were respectively added therein;    -   c) 12 μl of Lipo LTX and 250 μl of Opti-MEM™ medium were added        without contacting the tube wall, and they were mixed uniformly        through blowing and pipetting by a pipetting gun;    -   d) the agent mixed with DNA Plus (see Step 3.2.b) was added into        the diluted LipoLTX (see Step 3.2.c) transfection agent, and        stood still for 15 min at room temperature;    -   e) the transfection agent mixed with DNA was added to a 60-mm        cell culture dish (see Step 3.1); and    -   f) the culture dish was placed into an incubator at 37° C. and        5% CO₂ and cultured for 5 h.

3.3 Compound Treatment

-   -   a) 150 nl of the diluted compound (see Step 2.3) was transferred        by Echo550 to a cell culture plate (6007680-50, PE);    -   b) the cells (see Step 3.2) were seeded to a 384 cell culture        plate (6007680-50, PE), with 15,000 cells and 25 μl of the        medium containing 5% fetal bovine serum per well; and    -   c) the cells were cultured overnight in an incubator at 37° C.        and 5% CO₂.

3.4 Compound Detection

-   -   a) The Steady-Glo™ detection agent was placed at room        temperature;    -   b) the 384 cell plate (see Step 3.3) was placed at room        temperature;    -   c) 25 μl of the Steady-Glo™ detection agent per well was added        into the cell culture plate (see Step 3.4b);    -   d) the plate was placed on a shaker and shaken for 5 min while        protected from light; and    -   e) the chemiluminescence value was detected with the Envision        2104 microplate reader.

4. Data Analysis

4.1 Calculation of Activity (%):

${{Activity}(\%)} = {\left\lfloor \frac{{RLU}_{compound} - {\overset{\_}{RLU}}_{blank}}{{\overset{\_}{RLU}}_{positive} - {\overset{\_}{RLU}}_{blank}} \right\rfloor \times 100}$

-   -   RLU: Fluorescence generated    -   RLU _(compound): Well average of embodiment compounds    -   RLU _(positive): positive control average    -   RLU _(blank): negative control average

4.2 EC50 Calculation and Plotting of Dose-Effect Curve of the Compound

EC50 of the the compound was calculated by using Graphpad 5.0 to fit theactivity (%) and the logarithm concentration of the compound.

Y=bottom+(top−bottom)/(1+10{circumflex over ( )}((Log IC50−X)×slope))

-   -   X: Logarithm concentration of the compound Y: Percentage        inhibition rate

Particular test data are shown in Table 1 as follows.

Test Embodiment 3 Binding Force of the Compound to TRβ Test

1. Main Experimental Material and Apparatus:

-   -   Envision 2104 microplate reader,    -   Biotin-SRC2-2 coactivator peptide, commercially available from        Sangon Biotech (Shanghai) Co., Ltd.    -   TRβ LBD, GST, commercially available from ThermoFisher (Art. No.        PV4762)    -   Europium binding anti-glutathione antibody, commercially        available from Cisbio (Art. No. 61GSTKLB)    -   Streptavidin-D2, commercially available from Cisbio (Art. No.        610SADAB)

2. Preparation and Treatment of Compounds

2.1 Preparation of Stock Solution of the Compound in Dimethyl Sulfoxide

All compounds were dissolved in dimethyl sulfoxide to prepare a 10 mmolstock solution.

2.2 Compound Storage

After the compounds were dissolved in dimethyl sulfoxide, the solutioncan be stored for 3 months in a desiccator at room temperature. Forlong-term storage, compounds shall be placed into a refrigerator at −20°C.

3. Experimental Steps

3.1 Preparation of 1× Reaction Buffer

3.2 Compound Screening:

-   -   a) 100% dimethyl sulfoxide was used to dilute the positive drug        triiodothyronine (T3) from 10 μmol (100×) or the compound to be        tested from 1 mmol (100×), at an equal ratio of 1:3, totally in        10 concentrations;    -   b) A 4× concentration gradient diluted compound was prepared        with a 1× reaction buffer;    -   c) 5 μl of the 4× concentration gradient diluted compound was        added into a 384-well test plate;    -   d) 4×TRβ LBD and 4×RXRβ were prepared with the 1× reaction        buffer;    -   e) 5 μl of 4×TRβ LBD and 4×RXRβ were added into the 384-well        test plate;    -   f) 2× biotin-SRC2-2, 2× Europium binding anti-glutathione        antibody and 2× streptavidin-d2 were prepared with the 1×        reaction buffer;    -   g) 10 μl of a 2× mixed solution (referring to Step f) was added        into the 384-well test plate;    -   h) The 384-well test plate was centrifugated for 1000        revolutions within 1 min in a centrifuge;    -   i) Incubation at room temperature was performed for 1 h, while        protected from light; and    -   j) The fluorescence signal values of each well of the 384-well        test plate at the wavelength of 665 nm and 615 nm were recorded        with the Envision 2104 microplate reader, and the fluorescence        ratio of 665 nm/615 nm was calculated.

4. Data Analysis

4.1 Calculation of Relative Ratio (ratio_(665 nm/615 nm)-ratio_(blank))of Each Well

4.2 The Activity Percentage was Calculated as Follows:

${{Activity}(\%)} = {\left\lfloor \frac{{Ratio}_{compound} - {\overset{\_}{Ratio}}_{blank}}{{\overset{\_}{Ratio}}_{positive} - {\overset{\_}{Ratio}}_{blank}} \right\rfloor \times 100}$

-   -   Ratio _(compound): average of relative ratios of wells of        embodiment compounds    -   Ratio _(positive): average of relative ratios of all positive        control wells    -   Ratio _(blank): average of relative ratios of all negative        control wells

4.3 Curve Plotting and EC50 Calculation:

EC50 was calculated by using Graphpad 5.0 through the nonlinearregression method to fit the relationship between the activity (%) andthe logarithm concentration of the compound.

Y=bottom+(top−bottom)/(1+10{circumflex over ( )}((Log EC50−X)×slope))

-   -   X: Logarithm concentration of the compound Y: Percentage        activity

Particular test data are shown in Table 1 as follows.

Table 1 The binding activity of the compound to the thyroxine receptor βis shown as follows:

IC50 THRβ THRα THRα/β binding force binding force selectivityEmbodiments (μM) (μM) (factor) Embodiment 1 1.23 >10 > 8.1 Embodiment 22.33 >10 >4.29 Embodiment 3 5.2 >10 >1.92 Embodiment 4 0.36 4.3 >11.9Embodiment 9 0.17 >10 >58.8 Embodiment 10 1.47 >10 >6.80 Embodiment 111.78 >10 5.61 Embodiment 12 0.80 0.2 0.25 Embodiment 13 0.17 1.22 7.17Embodiment 14 0.262 Comparative 0.26 5.0 19.2 Compound 53 T3 0.000520.00026

Conclusion: compared with the disclosed comparative compound 53, some ofthe compounds according to the present invention unexpectedly showedhigh THRβ activity (<0.2 μM), and some of the compounds showed higherselectivity to THRα than the comparative compound 53.

Test Embodiment 4 Evaluation of Agonistic Activity of the CompoundToward the TRβ Receptor

Experiment Summary: TRβ-LBD and RXRα-LBD coding sequences were insertedinto a pBIND plasmid (Promega, E1581) respectively. The expressionvector and the reporter vector (pGL4.35 carrying a luciferase reportergene driven by a stable integrated GAL4 promoter) were co-expressed inthe host cell. When the agonist binds to the corresponding chimericreceptor, the chimeric receptor binds to the GAL4 binding site on thereporter gene vector and stimulates the reporter gene expression.According to the intensity of chemiluminescence signals, the agonisticactivity of the compound toward the TRβ receptor was determined.

Experimental Materials and Apparatuses:

-   -   Envision 2104 microplate reader    -   HEK293T cell line, commercially available from ATCC (Art. No.:        CRL-3216)    -   pGL4.35[luc2P/9XGAL4 UAS/Hygro], commercially available from        Promega (Art. No.: E1370)    -   pBIND-TR β plasmid, from Pharmaron    -   pBIND-RXRα plasmid, from Pharmaron    -   LipoLTX transfection agent, commercially available from        ThermoFisher (Art. No.: 15338-100)    -   Steady-Glo™ luciferase detection kit, commercially available        from Promega (Art. No.: E2520)

2.3 Preparation of Experimental Compounds

-   -   All the compounds to be tested were diluted with dimethyl        sulfoxide at a 3-fold gradient, in 10 dilution gradients,        starting from the initial concentration of 10 mmol.    -   The positive control triiodothyronine (T3) was diluted with        dimethyl sulfoxide at a 3-fold gradient, in 10 dilution        gradients, starting from the initial concentration of 16.67        μmol.    -   A 166.7×positive control (16.67 μmol, triiodothyronine (T3)) and        a 166.7×negative control (100% dimethyl sulfoxide) were        prepared.    -   The compound plate was closed and shaken for 5 min.

Experiment Process

3.1 Cell Suspension Preparation and Plate Seeding

-   -   a) All cells were cultured according to the ATCC standard        operation, and HEK293T was tested in the exponential growth        period;    -   b) The medium was discarded;    -   c) The cells were washed twice with a phosphate buffer;    -   d) A trypsinization solution was added to digest the cells, and        the digestion was terminated with a complete medium;    -   e) The cells were collected and counted, and only when the cell        viability was greater than 90% could the experiment be carried        out;    -   f) 2.5×10⁶ HEK293-LUC cells were seeded into a 60-mm cell        culture dish; and    -   g) The culture dish with cells seeded was placed into an        incubator at 37° C. and 5% CO₂ and cultured overnight.

3.2 Cell Transfection

-   -   a) The LipoLTX transfection agent was placed at room temperature        for balancing;    -   b) 6 μl of Plus agent and 6 μg of DNA were added into 250 μl of        an Opti-MEM™ medium without contacting the tube wall, and they        were mixed uniformly through blowing and pipetting by a        pipetting gun; plasmid: 2.5 μg of pBIND-TRβ, 2.5 μg of        pBIND-RXRα and 1 μg of pGL4.35 plasmid    -   c) 12 μl of Lipo LTX and 250 μl of Opti-MEM™ medium were added        without contacting the tube wall, and they were mixed uniformly        through blowing and pipetting by a pipetting gun;    -   d) the agent mixed with DNA plus (see Step 3.2.b) was added into        the diluted LipoLTX (see Step 3.2.c) transfection agent and        stood still for 15 min at room temperature;    -   e) the transfection agent mixed with DNA was added to a 60-mm        cell culture dish (see Step 3.1); and    -   f) the culture dish was placed into an incubator at 37° C. and        5% CO₂ and cultured for 5 h.

3.3 Compound Treatment

-   -   a) 150 nl of the diluted compound (see Step 2.3) was transferred        by Echo550 to a cell culture plate (6007680-50, PE);    -   b) the cells (see Step 3.2) were seeded to a 384 cell culture        plate (6007680-50, PE) with 15,000 cells and 25 μl of the medium        per well; and    -   c) the cells were cultured overnight in an incubator at 37° C.        and 5% CO₂.

3.4 Compound Detection

-   -   a) The Steady-Glo™ detection agent was placed at room        temperature;    -   b) the 384 cell plate (see Step 3.3) was placed at room        temperature;    -   c) 25 μl of the Steady-Glo™ detection agent per well was added        into the cell culture plate (see Step 3.4b);    -   d) the plate was placed on a shaker and shaken for 5 min while        protected from light; and    -   e) the chemiluminescence value was detected with the Envision        2104 microplate reader.

Data Analysis

4.1 Calculation of Activity (%):

${{Activity}(\%)} = {\left\lfloor \frac{{RLU}_{compound} - {\overset{\_}{RLU}}_{blank}}{{\overset{\_}{RLU}}_{positive} - {\overset{\_}{RLU}}_{blank}} \right\rfloor \times 100}$

-   -   RLU: fluorescence generated    -   RLU _(compound): Well average of embodiment compounds    -   RLU _(positive): positive control average    -   RLU _(blank): negative control average

4.2 EC50 Calculation and Plotting of Dose-Effect Curve of the Compound

EC50 of the compound was calculated by using Graphpad 5.0 to fit theactivity (%) and the logarithm concentration of the compound.

Y=bottom+(top−bottom)/(1+10{circumflex over ( )}((Log IC50−X)×slope))

-   -   X: Logarithm concentration of the compound Y: Percentage        inhibition rate        Table 2: the agonistic activity of the compound of the present        invention toward the thyroxine receptor beta is shown as        follows:

EC₅₀ THRβ agonistic THRα agonistic Embodiments activity (μM) activity(μM) Embodiment 4 2.45 4.25 Embodiment 9 1.75 3.98 Embodiment 12 0.791.08 Embodiment 13 0.097 0.123 Comparative 2.48 4.57 Compound 53 T30.001 0.0005

Conclusion: the compound of the present invention can activate thedownstream signal of the thyroid hormone receptor beta.

Test Embodiment 5 Pharmacokinetic Evaluation

Rats were used as test animals. After intragastric infusion of thecompounds from Embodiment 4 and Embodiment 9, the drug concentrations inthe plasma of the rats at different times were tested. Thepharmacokinetic behaviors of the compounds of the present invention inrats were studied, and the pharmaceutical metabolism characteristicsthereof were evaluated. In each group of the embodiment, 3 male SD ratswith a similar body weight were selected, and the oral dose was 2 mg/kgin a single dose. Blood was collected at time points of 15 min, 30 min,1 h, 2 h, 4 h, 6 h, 10 h, and 24 h after administration of the dose tothe animals. The LC-MS/MS analytical method was employed to detect thecontent of the compounds in plasma, and the lower limit ofquantification of the method was 20 ng/ml. The metakinetic data analysissoftware WinNonlin 7.0 was used to generate statistics on VT088 andconcentration data of the plasma. The non-compartment model method (NCA)was utilized to calculate the pharmacokinetic parameters, particularlyas shown in Table 2 below.

Experiment Scheme:

Experiment Drugs: compounds from Embodiment 4 and Embodiment 9.

Laboratory Animals:

-   -   Six healthy male SD rats, commercially available from Shanghai        Sippr-Bk Laboratory Animal Co., Ltd., with an animal production        license No.: SOCK(Shanghai) 2008-0016, were divided into 2        groups, 3 in each group.    -   Drug Preparation: a certain amount of the drug was taken and        added into a 2% Klucel LF+0.1% Tween 80 aqueous solution, to        prepare a clear solution or a uniform suspension.    -   Dosage: SD rats were fasted overnight and given the drug by        intragastric infusion at an administrated dose of 2 mg/kg and an        administrated volume of 10 mL/kg each.    -   Operation: rats were dosed by intragastric infusion with the        compounds from Embodiment 4 and Embodiment 9. At least 0.2 mL of        blood was collected from the vena caudalis at 15 min, 30 min, 1        h, 2 h, 4 h, 6 h, 10 h, and 24 h before and after the dosage;        the blood was then placed in heparinized sample tubes,        centrifuged at 4° C. and 3500 rpm for 10 min to separate the        plasma. The heparinized sample tubes were then stored at −20°        C., and the rats were allowed to eat food 2 h after the dosage.

Determination of contents of the compounds to be tested in the plasma ofrats after intragastric infusion of the drugs at differentconcentrations: the plasma samples were thawed at room temperature, 50μL each was taken and added into 130 μL of an internal standard workingsolution (1000 ng/mL, acetonitrile, tolbutamide), and the mixture waswhirled for about 1 min and then centrifugated at 4° C. and 13000 rpmfor 10 min. 50 μL of the supernatant was taken and mixed with 100 μL of50% acetonitrile water, and then introduced for LC/MS/MS analysis.

Results of the pharmacokinetic parameters are shown in Table 3.

TABLE 3 Pharmaceutical metabolism data of rats Peak blood drug Half-Dose Time to peak concentration Curve area life Compound (mg/kg) (h)(ng/ml) (ng · h/mL) (h) Embodiment 4 2.0 5.33 ± 1.15 727 ± 183 9242 ±1245 5.14 ± 0.83 Embodiment 9 2.0 4.67 ± 1.15 2007 ± 106  24790 ± 3704 4.56 ± 0.42 Comparative 2.0  5.3 ± 1.15 1163 ± 97.1  12854 ± 961  3.53 ±0.42 Compound 53

Conclusion: the compounds of the present invention possess goodpharmacokinetic absorption and significant pharmacokinetic advantages.Compared with the reported comparative compound 53, some of thecompounds of the present invention unexpectedly show higher Cmax valuesand exposure amounts at the same dose and preparation. All the above PKresults show that, the compounds provided in the present invention havegood PK properties and can be used as a therapeutic drug for ametabolism-related disease.

1. A compound represented by the following Formula (I) and apharmaceutically acceptable salt thereof,

wherein, R₁ is selected from the group consisting of hydrogen, cyano,substituted or unsubstituted C₁₋₆ alkyl, or substituted or unsubstitutedC₃₋₆ cycloalkyl, the substituent being selected from the groupconsisting of halogen atoms, hydroxy, and C₁₋₆ alkoxy; R₂ and R₃ areeach independently selected from the group consisting of halogen atomsor substituted or unsubstituted C₁₋₆ alkyl, the substituent beingselected from the group consisting of halogen atoms, hydroxy, and C₁₋₆alkoxy; ring A is a substituted or unsubstituted saturated orunsaturated C₅₋₁₀ aliphatic ring, or a substituted or unsubstitutedC₅₋₁₀ aromatic ring, the substituent being one or more substancesselected from the group consisting of hydrogen, halogen atoms, hydroxy,—OCF₃, —NH₂, —NHC₁₋₄ alkyl, —N(C₁₋₄ alkyl)₂, —CONH₂, —CONHC₁₋₄ alkyl,—CON(C₁₋₄ alkyl)₂, —NHCOC₁₋₄ alkyl, C₁₋₆ alkyl, C₁₋₆ alkoxy or C₃₋₆cycloalkyl, and when two substituents are contained, the twosubstituents can form a ring structure together with the carbonconnected thereto; and the halogen atoms are selected from the groupconsisting of F, Cl or Br.
 2. The compound and pharmaceuticallyacceptable salt thereof according to claim 1, wherein the compound has astructure as shown in the following Formula (II):

wherein, R₁ to R₃ are defined as described in claim 1; L is not presentor is selected from the group consisting of —CH₂— and —CH₂CH₂—; R₄ isselected from the group consisting of hydrogen, halogen atoms, hydroxy,—OCF₃, —NH₂, —NHC₁₋₄ alkyl, —N(C₁₋₄ alkyl)₂, C₁₋₆ alkyl, C₁₋₆ alkoxy orC₃₋₆ cycloalkyl; n is an integer from the range 1 to 4; m is an integerfrom the range 1 to 4; when L is not present, the ring may have two ormore substituents R₄ thereon; and the halogen atoms are selected fromthe group consisting of F, Cl or Br.
 3. The compound andpharmaceutically acceptable salt thereof according to claim 2, whereinR₄ is selected from the group consisting of hydrogen, halogen atoms,hydroxy, C₁₋₃ alkyl, C₁₋₃ alkoxy or C₃₋₆ cycloalkyl; L is not present oris selected from the group consisting of —CH₂— or —CH₂CH₂—; n is 1, 2 or3; and m is 1 or
 2. 4. The compound and pharmaceutically acceptable saltthereof according to claim 3, wherein R₄ is selected from the groupconsisting of hydrogen or C₁₋₃ alkyl; L is not present; n is 1, 2 or 3;and m is 1 or
 2. 5. The compound and pharmaceutically acceptable saltthereof according to claim 3, wherein R₄ is selected from the groupconsisting of hydrogen or C₁₋₃ alkyl; L is selected from the groupconsisting of —CH₂— or —CH₂CH₂—; n is 1, 2 or 3; and m is 1 or
 2. 6. Thecompound and pharmaceutically acceptable salt thereof according to claim1, wherein the compound has a structure as shown in the followingFormula (III):

wherein, R₁ to R₃ are defined as described in claim 1; R₄ is selectedfrom the group consisting of hydrogen, halogen atoms, hydroxy, —OCF₃,—NH₂, —NHC₁₋₄ alkyl, —N(C₁₋₄ alkyl)₂, —CONH₂, —CONHC₁₋₄ alkyl, —CON(C₁₋₄alkyl)₂, —NHCOC₁₋₄ alkyl, C₁₋₆ alkyl, C₁₋₆ alkoxy or C₃₋₆ cycloalkyl; mis an integer from the range 1 to 4; and the halogen atoms are selectedfrom the group consisting of F, Cl or Br.
 7. The compound andpharmaceutically acceptable salt thereof according to claim 6, whereinR₄ is selected from the group consisting of hydrogen, halogen atoms,hydroxy, —OCF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy or C₃₋₆ cycloalkyl; and m is aninteger from the range 1 to
 3. 8. The compound and pharmaceuticallyacceptable salt thereof according to claim 7, wherein R₄ is selectedfrom the group consisting of hydrogen, halogen atoms or C₁₋₃ alkyl; andm is 1 or
 2. 9. The compound and pharmaceutically acceptable saltthereof according to any one of claims 1 to 8, wherein R₁ is selectedfrom the group consisting of hydrogen, cyano, and substituted orunsubstituted C₁₋₆ alkyl, the substituent being selected from the groupconsisting of halogen atoms, hydroxy, and C₁₋₆ alkoxy; and the halogenatoms are selected from the group consisting of F, Cl or Br.
 10. Thecompound and pharmaceutically acceptable salt thereof according to claim9, wherein R₁ is selected from the group consisting of cyano or C₁₋₃alkyl.
 11. The compound and pharmaceutically acceptable salt thereofaccording to claim 10, wherein R₁ is cyano.
 12. The compound andpharmaceutically acceptable salt thereof according to any one of claims1 to 8, wherein R₂ and R₃ are each independently selected from the groupconsisting of F, Cl or Br.
 13. The compound and pharmaceuticallyacceptable salt thereof according to claim 12, wherein R₂ and R₃ areboth Cl.
 14. The compound and pharmaceutically acceptable salt thereofaccording to any one of claims 1 to 13, wherein the compound andpharmaceutically acceptable salt thereof are one of the followingcompounds:


15. Use of the compound and pharmaceutically acceptable salt thereofaccording to any one of claims 1 to 14 in the preparation of atherapeutic drug for a metabolism-related disease.
 16. The use of thecompound and pharmaceutically acceptable salt thereof according to claim15 in the preparation of the therapeutic drug for the metabolism-relateddisease, wherein the metabolism-related disease is selected from thegroup consisting of obesity, hyperlipidemia, hypercholesterolemia,diabetes, and non-alcoholic steatohepatitis (NASH), steatosis of liver,atherosclerosis, hypothyroidism, and thyroid cancer.
 17. The use of thecompound and pharmaceutically acceptable salt thereof according to claim16 in the preparation of the therapeutic drug for the metabolism-relateddisease, wherein the metabolism-related disease is selected from thegroup consisting of non-alcoholic steatohepatitis (NASH),hypothyroidism, and thyroid cancer.
 18. A pharmaceutical composition,comprising a therapeutically effective amount of the compound andpharmaceutically acceptable salt according to any one of claims 1 to 14,and a pharmaceutically acceptable adjuvant.
 19. A method for treating ametabolism-related disease, the method comprising administering to thesubject an effective amount of the compound according to any of claims 1to 14, or a pharmaceutical composition containing the compound andpharmaceutically acceptable salt thereof as the active ingredient. 20.The method for treating a metabolism-related disease according to claim19, wherein the metabolism-related disease is selected from the groupconsisting of obesity, hyperlipidemia, hypercholesterolemia, diabetes,and non-alcoholic steatohepatitis (NASH), steatosis of liver,atherosclerosis, hypothyroidism, and thyroid cancer.
 21. The method fortreating a metabolism-related disease according to claim 20, wherein themetabolism-related disease is selected from the group consisting ofnon-alcoholic steatohepatitis (NASH), hypothyroidism, and thyroidcancer.